InvestmentJul 28, 2026, 01:12 PM
GSK Invests £400M in UK R&D, New Cambridge Site
AI Summary
GSK announced a significant investment of £400 million over three years to accelerate its R&D pipeline in the UK. This includes establishing a new 300,000 square foot R&D site on the Cambridge Biomedical Campus, which will house over 1,000 scientists and focus on key therapeutic areas. The company will vacate its Stevenage R&D site by 2029 and upgrade its existing R&D labs at Ware, Hertfordshire, to create integrated drug development capabilities. This strategic move aims to integrate GSK further into a world-leading life sciences ecosystem.
Key Highlights
- GSK to invest £400 million over 3 years in UK R&D operations.
- A new 300,000 sq ft R&D site will be established on Cambridge Biomedical Campus.
- Over 1,000 GSK scientists will be based at the new Cambridge facility.
- GSK will vacate its R&D site at Stevenage, Hertfordshire, by 2029.
- Existing R&D laboratories at Ware, Hertfordshire, will be upgraded.
- The Cambridge site will focus on Oncology, Respiratory, Hepatology, Vaccines, and HIV.
- GSK invests over £6 billion in R&D annually, with over £1.5 billion in the UK.
Price Impact
More from GSK